Xontogeny
Overview
Xontogeny is a life sciences accelerator and investment firm that provides seed capital, strategic guidance, and operational support to early-stage companies developing therapeutics, diagnostics, and medical devices.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Avalyn Pharma | Sep 2023 | Series C | Lead |
| Cargo Therapeutics | Mar 2023 | Series A | Lead |
| CereVasc | May 2024 | Series B | Co-investor |
| Neurosterix | Apr 2024 | Series A | Lead |
| Peroxitech | Dec 2022 | Series A | Co-investor |
For institutional investors. Book with your work email.
Key People
Chris Garabedian
Chairman and CEO
Gianna Hoffman-Luca
Partner
Heather Antioquia
Vice President, Program Development
Takeru Furuya
Principal Entrepreneur-in-Residence Advisor
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Xontogeny based?
Xontogeny is headquartered in Boston, Massachusetts, United States.
When was Xontogeny founded?
Xontogeny was founded in 2016.
How many portfolio companies does Xontogeny have?
Xontogeny has 14 portfolio companies in Caplight's dataset.
What are some companies in Xontogeny's portfolio?
Portfolio companies visible on Caplight include Avalyn Pharma, Cargo Therapeutics, CereVasc, Neurosterix, Peroxitech.
What was Xontogeny's most recent investment shown here?
Xontogeny's most recent investment in this portfolio sample was in CereVasc in 2024.
What sectors does Xontogeny focus on?
Xontogeny focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Xontogeny focus on?
Xontogeny typically invests at the Early stage.
What is Xontogeny's AUM?
Xontogeny's assets under management are estimated between $500.0M and $1.0B.